Drugs / TQB3823
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05021367 | Sep 2021 → Feb 2025 | neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05405439 | Aug 2022 → Jul 2023 | castration-resistant prostate carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3823 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05021367 ↗ |
| Action | Inhibit | “can inhibit the enzyme activity of PARP1/2” NCT05021367 ↗ |
| Modality | Small molecule | “TQB3823 is a small molecule” NCT05021367 ↗ |
| Target | PARP1 | “inhibit the enzyme activity of PARP1/2” NCT05021367 ↗ |